Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST
John R Zalcberg, Jayesh Desai
Asia Pacific Journal of Clinical Oncology | WILEY | Published : 2012
John R. Zalcberg has received research support, honoraria and travel support from Novartis and Pfizer. He has attended advisory board meetings for Novartis and Pfizer. Jayesh Desai has received research support and honoraria from Novartis and Pfizer. He has also provided consultancy and attended advisory board meetings for Novartis and Pfizer.Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Angelo Russo for his medical editorial assistance with this manuscript.